Wall Street expects a year-over-year increase in earnings on higher revenues when AtriCure (ATRC) reports results for the quarter ended December 2024. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on February 12. ...

财务业绩发布 - AtriCure公司于2025年1月13日发布了2024年第四季度及全年初步财务业绩 [4] 投资者会议与业务讨论 - 公司正在与投资者举行会议，讨论业务概览和增长战略 [6] 前瞻性声明与免责声明 - 投资者演示文稿和新闻稿中包含有关公司未来事件和业绩的前瞻性声明 [7] - 公司不承担更新或修订任何财务或其他预测或前瞻性声明的义务 [7] 信息参考与文件提交 - 新闻稿和投资者演示文稿的信息仅供参考，不构成正式文件 [8] - 公司提交了2025年1月13日的新闻稿和投资者演示文稿作为附件 [9]

财务业绩 - 国际销售增长24.8%(按固定汇率基准增长24.6%)，涵盖所有业务和主要地理区域[81] - 2024年前9个月经营活动产生的现金流量净额较2023年增加591.4万美元,主要是非现金费用增加763.3万美元,以及营运资金和其他资产负债变动减少676.2万美元[86] - 2024年前9个月投资活动产生的现金流量净额较2023年增加2,032.4万美元,主要是2023年支付3,000万美元收购知识产权,以及可供出售证券的销售和到期减少1,014.7万美元[87] - 2024年前9个月筹资活动产生的现金流量净额较2023年增加295万美元,主要是偿还债务和支付融资费用162.3万美元,以及行权和员工股票购买计划收款减少99.8万美元[88] - 截至2024年9月30日,公司现金、现金等价物和投资为1.30亿美元,未使用的借款额度为6,188.5万美元[85] 费用增加 - 研发费用增加8,102万美元或15.3%,主要是产品开发、监管和临床团队人员成本增加5,305万美元,临床试验费用增加3,448万美元[82] - 销售、一般及管理费用增加33,723万美元或18.2%,主要是人员成本(包括差旅和股份支付)增加22,763万美元,以及专业服务、IT和企业成本增加1,877万美元[83] 债务清算 - 公司在2024年第一季度确认了136.2万美元的债务清算损失[84] - 公司于2024年1月5日与银行签订了1.25亿美元的资产担保循环信贷额度,截至2024年9月30日已借款6,186.5万美元[89]

财务数据和关键指标变化 - 第三季度总收入为1.16亿美元，同比增长约18% [6] - 调整后EBITDA为800万美元，较2023年第三季度的470万美元增长68% [24] - 现金流超过1600万美元，标志着连续第二个季度的正现金流 [7][25] 各条业务线数据和关键指标变化 - 疼痛管理业务全球增长36%，国际市场表现突出 [8] - 开放消融业务全球增长16%，美国Encompass夹具销售增长近50% [11] - 附件管理业务全球增长18%，美国开放式附件管理设备销售增长20% [12] 各个市场数据和关键指标变化 - 美国市场收入为9550万美元，同比增长16.8% [20] - 国际市场收入为2050万美元，同比增长23.3% [22] - 欧洲市场销售增长33%，亚太及其他国际市场增长12% [22] 公司战略和发展方向和行业竞争 - 公司计划通过持续创新和临床科学推动增长，特别是在疼痛管理和心房颤动治疗领域 [17][16] - 进入PFA技术的独家许可和开发协议，预计将成为心脏手术设备的基础元素 [25][51] - 竞争被视为市场增长的推动力，增强了对治疗的意识 [44] 管理层对经营环境和未来前景的评论 - 管理层对未来的展望乐观，预计2024年总收入将达到4.59亿至4.62亿美元 [7][26] - 预计2025年将看到更多患者需要治疗，尤其是在PFA技术的推广下 [32] 其他重要信息 - 公司在第三季度推出了新的AtriClip FLEX Mini设备，市场反馈积极 [13] - 公司在LeAAPS临床试验中已招募3700名患者，预计到2025年中期完成6500名患者的招募 [14] 问答环节所有提问和回答 问题: 关于PFA的趋势 - 管理层认为PFA的引入将导致MIS消融和MIS夹具业务的压力，但未来会有更多患者需要治疗 [31][32] 问题: PFA合作伙伴的细节 - 目前尚未透露合作伙伴的具体信息，但管理层对技术的进展充满信心 [34][35] 问题: Encompass夹具的增长 - Encompass夹具在美国市场增长约50%，预计未来在欧洲市场也会有积极影响 [36][38] 问题: PFA合作对现金流的影响 - 管理层表示此次投资是整体研发计划的一部分，不会改变现金流的预期 [40][41] 问题: AtriClip业务的竞争动态 - 竞争的存在促进了市场的整体增长，管理层对AtriClip产品的质量和市场前景充满信心 [58][60] 问题: Encompass夹具在CABG市场的渗透率 - 目前CABG市场的渗透率约为30%至35%，仍有很大的增长空间 [62]

For the quarter ended September 2024, AtriCure (ATRC) reported revenue of $115.91 million, up 17.9% over the same period last year. EPS came in at -$0.17, compared to -$0.20 in the year-ago quarter. The reported revenue represents a surprise of +2.95% over the Zacks Consensus Estimate of $112.59 million. With the consensus EPS estimate being -$0.20, the EPS surprise was +15.00%. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall S ...

AtriCure (ATRC) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.20 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 15%. A quarter ago, it was expected that this medical device maker would post a loss of $0.15 per share when it actually produced a loss of $0.17, delivering a surprise of -13.33%. Over the last four quarters, the company has su ...

Exhibit 99.1 For immediate release October 29, 2024 AtriCure Reports Third Quarter 2024 Financial Results • Worldwide revenue of $115.9 million – an increase of 17.9% year over year • U.S. revenue of $95.5 million – an increase of 16.8% year over year • Achieved 20% growth on revenues from open appendage management devices in the U.S. • International revenue of $20.5 million – an increase of 23.3% year over year • Positive cash flow generation of $16.3 million in third quarter 2024 MASON, Ohio, October 29, ...

AtriCure, Inc. (ATRC)  has launched the cryoSPHERE MAX cryoablation probe, which enhances Cryo Nerve Block (cryoNB) therapy by reducing freeze times by 50% compared to previous models and over 30% when compared to the cryoSPHERE+ probe.cryoNB therapy, using AtriCure’s cryoICE technology, is a non-pharmacological method to freeze targeted intercostal nerves, providing temporary pain relief along peripheral nerve pathways.The cryoSPHERE MAX device, part of AtriCure’s cryoNB therapy, cuts ablation time by 50% ...

AtriCure, Inc. (ATRC) , a leading innovator in surgical treatments for atrial fibrillation (Afib), has announced regulatory approval for its EnCompass Clamp in CE-marked countries within the European Union.European surgeons have already performed the first series of cases using the device. Initially launched in the United States in 2022, the EnCompass Clamp is designed to streamline heart ablation during open-chest surgeries.The EnCompass Clamp incorporates key features of AtriCure’s Synergy Clamp family, i ...

AtriCure, Inc. (ATRC) recently announced the treatment of the first patient with the AtriClip FLEX-Mini device. The device recently received the FDA 510(k) clearance.The AtriClip FLEX-Mini, the smallest surgical left atrial appendage (LAA) device available, raises the standard with its easy-to-use, simple design that provides physicians with better visibility and access. It builds on the well-proven technology of AtriCure's AtriClip platform.The recent developments regarding AtriCure’s ArtiClip devices are ...